Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

DE:L9S Stock Latest News

Company AnnouncementsGyre Therapeutics Secures CEO and CFO with New Contracts1w ago8K GYRE

Company AnnouncementsGyre Therapeutics Highlights Capital-Efficient Global Development Strategy2M ago8K GYRE
Company AnnouncementsGyre Therapeutics unveils capital-efficient global development strategy2M ago8K GYRE
Company AnnouncementsThin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks2M agoGYRE
Company AnnouncementsGyre Therapeutics Strengthens Board with New Director Appointments3M ago8K GYRE

Gyre Therapeutics files to sell 30.22M shares of common stock for holders

The FlyGyre Therapeutics files to sell 30.22M shares of common stock for holders4M agoGYRE

Company AnnouncementsGyre Therapeutics Shareholders Approve Directors and Governance Measures4M ago8K GYRE

Company AnnouncementsGyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy5M ago8K GYRE

Company AnnouncementsGyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion5M ago8K GYRE
Company AnnouncementsGyre Therapeutics’ F351 NDA Accepted for Priority Review5M ago8K GYRE
The FlyGyre Therapeutics announces China NMPA acceptance of F351 NDA5M agoGYRE
The FlyGyre Therapeutics reports Q1 EPS (10c) vs. 0c last year5M agoGYRE

GYRE Upcoming Earnings Report: What to Expect?

Pre-EarningsGYRE Upcoming Earnings Report: What to Expect?6M agoGYRE

Company AnnouncementsGyre Therapeutics Completes Cullgen Acquisition and Leadership Transition6M ago8K GYRE

Company AnnouncementsGyre Therapeutics Files NDA in China for F3517M ago8K GYRE

RatingsBuy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval7M agoGYRE
The FlyGyre Therapeutics’ liver fibrosis candidate granted priority review in China7M agoGYRE
Company AnnouncementsGyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions7M agoGYRE
Company AnnouncementsGyre Therapeutics Projects Strong Growth for Fibrosis Programs7M ago8K GYRE

Gyre Therapeutics reports Q4 EPS (2c), consensus 1c

The FlyGyre Therapeutics reports Q4 EPS (2c), consensus 1c7M agoGYRE

The FlyGyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M7M agoGYRE

Company AnnouncementsGyre Therapeutics to Acquire Cullgen in All-Stock Merger8M ago8K GYRE